Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Aditxt, Inc. (ADTX) has issued an update.
Aditxt, Inc. has entered into an agreement to acquire all issued and outstanding shares of Appili Therapeutics, Inc. through its subsidiary Adivir, Inc. in a transaction featuring both cash and stock considerations. Appili shareholders are set to receive $0.0467 per share and a fractional common stock of Aditxt, totaling $5,668,222 and 332,876 shares, respectively. The transaction is structured as a statutory plan of arrangement and is contingent upon customary closing conditions, including Appili shareholder approval and a minimum of $20 million in financing by Aditxt. This strategic move is expected to create value for shareholders, with representations, warranties, and covenants typical for such deals, allowing for a smooth acquisition process barring any material adverse changes or legal impediments.
Learn more about ADTX stock on TipRanks’ Stock Analysis page.